Chemomab Therapeutics Ltd.

CMMB ·Healthcare, Drug Manufacturers - General
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016
Operating Activities
Net Income $-9.8M $-4.7M
Depreciation & Amortization — —
Depreciation — —
Amortization — —
Stock-Based Compensation $700.0K —
Net Cash from Operating Activities $-8.5M $-3.7M
Investing Activities
Capital Expenditures $34.0K $75.0K
Business Acquisitions — —
Net Cash from Investing Activities $-34.0K $78.0K
Financing Activities
Dividends Paid — —
Stock Repurchases — —
Net Cash from Financing Activities $5.2M $6.1M
Net Change in Cash — —
Free Cash Flow $-8.5M $-3.8M
← Newer Page 2 of 2 Older →